Correct its a bummer - 2 things delayed. Guess for me, looking at it as only Otezla having a great oral for psoriasis and they are expecting 1.5 billion in sales 2017. I hope this is the rate of Otezla sales when we get the 2B Prurisol oral results which hopefully are quite better - should strengthen leverage in a deal.

Yes, I'd like to see a partner for Kevetrin Ph 2. It sounds like they are doing a trial thats shortened to look for tumor reduction and P53 in tissue with the 3x/week dose and then partner it after that.

I think Bertolino is going to help get value from the drugs quicker than past management. Wish he had been around 2 years ago.